4,471 Shares in Medpace Holdings, Inc. $MEDP Acquired by Oak Associates Ltd. OH

Key Points

• Oak Associates Ltd. OH acquired a new position in Medpace Holdings, purchasing 4,471 shares valued at approximately $1.36 million.
• In recent transactions, insiders sold a total of 114,450 shares worth over $51.79 million, indicating significant insider selling activity.
• Analysts forecast a positive outlook, with several raising their price targets; the consensus rating remains "Reduce" with an average price target of $406.60.

Oak Associates Ltd. OH bought a new position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 4,471 shares of the company's stock, valued at approximately $1,362,000.

A number of other large investors have also bought and sold shares of the business. Whittier Trust Co. increased its stake in Medpace by 47.3% during the 1st quarter. Whittier Trust Co. now owns 109 shares of the company's stock worth $33,000 after purchasing an additional 35 shares in the last quarter. Benjamin Edwards Inc. increased its stake in Medpace by 3.1% during the 1st quarter. Benjamin Edwards Inc. now owns 1,201 shares of the company's stock worth $366,000 after purchasing an additional 36 shares in the last quarter. Assetmark Inc. increased its stake in Medpace by 24.9% during the 1st quarter. Assetmark Inc. now owns 216 shares of the company's stock worth $66,000 after purchasing an additional 43 shares in the last quarter. Proficio Capital Partners LLC increased its stake in Medpace by 6.4% during the 1st quarter. Proficio Capital Partners LLC now owns 777 shares of the company's stock worth $237,000 after purchasing an additional 47 shares in the last quarter. Finally, Park Avenue Securities LLC increased its stake in Medpace by 1.8% during the 1st quarter. Park Avenue Securities LLC now owns 2,749 shares of the company's stock worth $838,000 after purchasing an additional 48 shares in the last quarter. 77.98% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Medpace news, General Counsel Stephen P. Ewald sold 3,000 shares of the firm's stock in a transaction on Monday, July 28th. The stock was sold at an average price of $450.00, for a total transaction of $1,350,000.00. Following the completion of the sale, the general counsel owned 10,343 shares of the company's stock, valued at $4,654,350. This trade represents a 22.48% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Kevin M. Brady sold 12,000 shares of the firm's stock in a transaction on Thursday, July 24th. The shares were sold at an average price of $454.23, for a total value of $5,450,760.00. Following the sale, the chief financial officer directly owned 6,000 shares of the company's stock, valued at $2,725,380. This represents a 66.67% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 114,450 shares of company stock worth $51,791,251 in the last quarter. 20.30% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. TD Cowen reissued a "sell" rating and set a $366.00 target price (up from $283.00) on shares of Medpace in a research note on Wednesday, July 23rd. Barclays raised their price target on shares of Medpace from $300.00 to $450.00 and gave the stock an "equal weight" rating in a research note on Wednesday, July 23rd. William Blair reaffirmed a "market perform" rating on shares of Medpace in a research note on Wednesday, July 23rd. Deutsche Bank Aktiengesellschaft raised their price target on shares of Medpace from $270.00 to $430.00 and gave the stock a "hold" rating in a research note on Wednesday, July 23rd. Finally, Truist Financial raised their price target on shares of Medpace from $298.00 to $436.00 and gave the stock a "hold" rating in a research note on Wednesday, July 23rd. Two analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Reduce" and an average price target of $406.60.

Medpace Stock Up 0.9%

Shares of MEDP opened at $473.48 on Thursday. The stock has a market capitalization of $13.30 billion, a P/E ratio of 35.20, a P/E/G ratio of 2.95 and a beta of 1.42. Medpace Holdings, Inc. has a twelve month low of $250.05 and a twelve month high of $501.30. The company has a 50 day moving average of $389.02 and a 200-day moving average of $337.53.

Medpace (NASDAQ:MEDP - Get Free Report) last released its quarterly earnings data on Monday, July 21st. The company reported $3.10 EPS for the quarter, beating the consensus estimate of $3.00 by $0.10. The company had revenue of $603.31 million during the quarter, compared to the consensus estimate of $537.70 million. Medpace had a return on equity of 67.66% and a net margin of 18.74%.The firm's revenue for the quarter was up 14.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.75 EPS. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. On average, sell-side analysts anticipate that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.

Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.